Vol 8, No 3 (June 2019): Translational Lung Cancer Research

Original Article

18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis
Ming Zhao, Xiao-Feng Xin, Huan Hu, Xian-Hui Pan, Tang-Feng Lv, Hong-Bing Liu, Jian-Ya Zhang, Yong Song
Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis
Zimu Wang, Ping Zhan, Yanling Lv, Kaikai Shen, Yuqing Wei, Hongbing Liu, Yong Song
Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer
Akihiro Yoshimura, Junji Uchino, Koichi Hasegawa, Taisuke Tsuji, Shinsuke Shiotsu, Tatsuya Yuba, Chieko Takumi, Tadaaki Yamada, Koichi Takayama, Noriya Hiraoka
Whole genome sequencing revealed microbiome in lung adenocarcinomas presented as ground-glass nodules
Yijiu Ren, Hang Su, Yunlang She, Chenyang Dai, Dong Xie, Shavira Narrandes, Shujung Huang, Chang Chen, Wayne Xu
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer
Takefumi Komiya, Regan M. Memmott, Gideon M. Blumenthal, Wendy Bernstein, Marc S. Ballas, Roopa De Chowdhury, Guinevere Chun, Cody J. Peer, William D. Figg, David J. Liewehr, Seth M. Steinberg, Giuseppe Giaccone, Eva Szabo, Shigeru Kawabata, Junji Tsurutani, Arun Rajan, Phillip A. Dennis
Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study
Irena Tan, Thomas E. Stinchcombe, Neal E. Ready, Jeffrey Crawford, Michael B. Datto, Rebecca J. Nagy, Richard B. Lanman, Lin Gu, Jeffrey M. Clarke
EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
Kai Dong, Wenhua Liang, Shen Zhao, Minzhang Guo, Qihua He, Caichen Li, Haiqing Song, Jianxing He, Xiaojun Xia

Study Protocol

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial
Robert A. Belderbos, Paul Baas, Rossana Berardi, Robin Cornelissen, Dean A. Fennell, Jan P. van Meerbeeck, Arnaud Scherpereel, Heleen Vroman, Joachim G. J. V. Aerts, on behalf of the DENIM team